Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis
Completed
- Conditions
- Osteoporosis
- Registration Number
- NCT02271204
- Lead Sponsor
- Clinic of Endocrinology and Metabolic Disorders, Macedonia
- Brief Summary
This observational study assess the safety of intravenous Ibandronate (Bonviva) intermittent administration in patients with postmenopausal osteoporosis and the efficacy of IV Ibandronate (Bonviva treatment through relative lumbar spine and hip bone mineral densitometry form baseline at year 1)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 700
Inclusion Criteria
- Patients had post menopausal osteoporosis
- Patients had no contraindication for bisphosphonates
- Patients had been naive for ibandronate therapy
- Patients who have signed informed consent and are willing to share their data for data analysis
Read More
Exclusion Criteria
- Is not Ibandronate naïve
- Hypersensitivity to any component of the bisphosphonates Ibandronate;
- Administration of any investigational drug within 30 days preceding the first dose of the study drug.
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of Participants with Adverse Events and Serious Adverse Events as a Measure of Safety and Tolerability of intravenous Ibandronate intermittent administration in patients with postmenopausal osteoporosis end of observation 12 months
- Secondary Outcome Measures
Name Time Method